April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Minimum Dose of Intravitreal Injection of Bevacizumab Effective againstVascular Endothelial Growth Factor in Macaque Eyes
Author Affiliations & Notes
  • Taichiro Miyake
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Masashi Kakinoki
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Osamu Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Tomoko Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Hajime Kawamura
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Masahito Ohji
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Footnotes
    Commercial Relationships  Taichiro Miyake, None; Masashi Kakinoki, None; Osamu Sawada, None; Tomoko Sawada, None; Hajime Kawamura, None; Masahito Ohji, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5635. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Taichiro Miyake, Masashi Kakinoki, Osamu Sawada, Tomoko Sawada, Hajime Kawamura, Masahito Ohji; The Minimum Dose of Intravitreal Injection of Bevacizumab Effective againstVascular Endothelial Growth Factor in Macaque Eyes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5635.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the minimum dose necessary to effect on vascular endothelial growth factor (VEGF) at intravitreally bevacizumab injection of Macaque eyes.

Methods: : Bevacizumab (1.25 µg/50 µl), 1/1,000 as we usually use, was injected into the vitreous cavity of the right eyes of three cynomolgus macaques. Aqueous humor were obtained from the macaques just before injection and on days 1, 3, 7 and 14 after the injection. The bevacizumab and VEGF concentrations were measured using enzyme-linked immunosorbent assay. If VEGF did not decrease after the injection, the dose of intravitreal injection of bevacizumab was increased by 5 times.

Results: : VEGF concentrations did not change when 1.25µg of bevacizumab was injected. It decreased to undetectable level when 6.25µg of bevacizumab was injected nad remained in undetectable level for 3-7 days. The half-life of 6.25 µg of intravitreally injected bevacizumab was 3.5 days in the aqueous humor, which was similar to 2.8days in the 1.25 mg of intravitreally injected bevacizumab in the previous study.

Conclusions: : Intravitreal injection of 6.25 µg of bevacizumab seems to be enough to suppress VEGF, especially when it is used as pre-operative adjunct for vitrectomy for proliferative diabetic retinopathy.

Keywords: vascular endothelial growth factor • aqueous • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×